Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants
Status: | Recruiting |
---|---|
Conditions: | Obesity Weight Loss, Women's Studies |
Therapuetic Areas: | Endocrinology, Reproductive |
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | April 2016 |
End Date: | March 2017 |
Contact: | David A Kaufman, MD |
Email: | dak4r@virginia.edu |
Phone: | 4349245428 |
To evaluate the safety and tolerability of three different lactoferrin doses in preterm
infants
infants
Aim1: To evaluate the safety and tolerability of three different lactoferrin doses in
preterm infants
1. Lactoferrin related adverse events and serious adverse events
2. Number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day)
3. Episodes of not receiving enteral feedings for > 24 hours once feeding is initiated
Aim 2: To evaluate lactoferrin absorption and excretion.
1. Examine lactoferrin levels in saliva, urine, plasma and stool
2. Examine lactoferrin levels in maternal and human donor milk.
Aim 3: To evaluate the effect of lactoferrin on the intestinal microbiome structure.
preterm infants
1. Lactoferrin related adverse events and serious adverse events
2. Number of infants reaching full feeds while receiving lactoferrin (120 ml/kg/day)
3. Episodes of not receiving enteral feedings for > 24 hours once feeding is initiated
Aim 2: To evaluate lactoferrin absorption and excretion.
1. Examine lactoferrin levels in saliva, urine, plasma and stool
2. Examine lactoferrin levels in maternal and human donor milk.
Aim 3: To evaluate the effect of lactoferrin on the intestinal microbiome structure.
Inclusion Criteria:
- < 15 days of age and receiving enteral feedings
- < 1500 grams birth weight
- <37 weeks gestation
Exclusion Criteria:
- Congenital bowel obstruction ( esophageal, duodenal, small bowel or anal atresias,
Hirschsprung disease, malrotation)
- Known necrotizing enterocolitis or bowel perforation
We found this trial at
2
sites
Click here to add this to my saved trials
Charlottesville, Virginia 22908
Principal Investigator: David Kaufman, MD
Phone: 434-924-9114
Click here to add this to my saved trials